• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Natera Inc. (Amendment)

    2/9/23 11:27:45 AM ET
    $NTRA
    Medical Specialities
    Health Care
    Get the next $NTRA alert in real time by email
    SC 13G/A 1 tv01475-naterainc.htm SCHEDULE 13G/A naterainc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 5)*

    Name of issuer:  Natera Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  632307104

    Date of Event Which Requires Filing of this Statement: December 30, 2022

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  632307104

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    46,739

    7.  SOLE DISPOSITIVE POWER

    9,794,233

    8.  SHARED DISPOSITIVE POWER

    151,281

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    9,945,514

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    9.01%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Natera Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    13011 McCallen Pass, Building A, Suite 100
    Austin, TX 78753

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    632307104

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2023

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $NTRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NTRA

    DatePrice TargetRatingAnalyst
    3/13/2025$251.00Outperform
    RBC Capital Mkts
    1/23/2025$200.00Overweight
    Barclays
    6/3/2024$142.00Buy
    Jefferies
    4/8/2024$117.00Buy
    Craig Hallum
    2/20/2024$68.00 → $85.00Strong Buy → Outperform
    Raymond James
    12/29/2023$75.00 → $85.00Buy
    BTIG Research
    12/14/2023$70.00Buy
    Guggenheim
    12/13/2023$70.00Outperform
    Wolfe Research
    More analyst ratings

    $NTRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting

      Studies include nearly 25,000 patients across multiple indications, showcasing the clinical impact of Signatera Breast: 8 accepted abstracts (4 oral presentations), including interim analysis from the randomized Signatera-guided interventional DARE trial; a large real-world study of metastatic treatment monitoring; and two readouts from the ISPY-2 trial Signatera Genome: Large-scale, pan-cancer performance of Signatera Genome assay GI, GU, Skin, Sarcoma: Significance of Signatera MRD and dynamics to predict recurrence, progression, and treatment response across multiple disease subtypes  Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today annou

      5/22/25 5:08:00 PM ET
      $NTRA
      Medical Specialities
      Health Care
    • Natera Reports First Quarter 2025 Financial Results

      Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the first quarter ended March 31, 2025. Recent Strategic and Financial Highlights Generated total revenues of $501.8 million in the first quarter of 2025, compared to $367.7 million in the first quarter of 2024, an increase of 36.5%. Product revenues grew 37.1% over the same period. Generated a gross margin of 63.1% in the first quarter of 2025, compared to a gross margin of 56.7% in the first quarter of 2024. Processed approximately 855,100 tests in the first quarter of 2025, compared to approximately 735,800 tests in the first quarter of 2024, an increase of

      5/8/25 4:05:00 PM ET
      $NTRA
      Medical Specialities
      Health Care
    • Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress

      Demonstrates Signatera's ability to predict long-term outcomes in early-stage, high-risk breast cancers Several datasets will be presented, highlighting Natera's leadership in breast cancer MRD Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, will present multiple datasets in breast cancer together with its collaborators at the 2025 ESMO Breast Cancer Annual Congress in Munich, Germany, taking place from May 14-17, 2025. Results from the I-SPY 2 clinical trial, sponsored and operated by Quantum Leap Healthcare Collaborative, will be shared in a mini-oral presentation on May 16, 2025. The report includes data from 712 patients with early-stage, high-ris

      5/8/25 10:30:00 AM ET
      $NTRA
      Medical Specialities
      Health Care

    $NTRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Natera Inc.

      SC 13G/A - Natera, Inc. (0001604821) (Subject)

      11/14/24 4:02:50 PM ET
      $NTRA
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Natera Inc. (Amendment)

      SC 13G/A - Natera, Inc. (0001604821) (Subject)

      6/7/24 12:07:25 PM ET
      $NTRA
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Natera Inc. (Amendment)

      SC 13G/A - Natera, Inc. (0001604821) (Subject)

      2/14/24 4:06:56 PM ET
      $NTRA
      Medical Specialities
      Health Care

    $NTRA
    Leadership Updates

    Live Leadership Updates

    See more
    • Experienced Biotech Executive and Deal Maker Joins Zephyr AI as Chief Business Officer

      Zephyr AI, Inc. ("Zephyr AI"), a company building novel transparent AI to address unmet needs across the full spectrum of precision medicine – from prevention to treatment – to improve patients' lives, today announced the appointment of Eric Lindquist as its new Chief Business Officer. "At Zephyr AI, we have set out to use artificial intelligence and machine learning to bring precision medicine to those suffering from cancer, and our goal is for patients everywhere to be able to find the right treatment, delivered by the right provider, when they need it, enabling them to live healthier and fuller lives," said Grant Verstandig, Co-Founder and Executive Chairman of Zephyr AI. "Eric has bee

      6/5/23 11:06:00 AM ET
      $NTRA
      Medical Specialities
      Health Care
    • Natera Appoints Ruth E. Williams-Brinkley to its Board of Directors

      Seasoned healthcare executive with extensive leadership experience in health plans, hospital operations, and physician relations Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing, today announced that Ruth E. Williams-Brinkley has been appointed to the Company's board of directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230223005436/en/(Photo: Business Wire) Williams-Brinkley has three decades of healthcare industry experience. She currently serves as president of Kaiser Permanente Health Plan of the Mid-Atlantic States (KPMAS), where she oversees the company's care delivery and health plan operations

      2/23/23 8:05:00 AM ET
      $NTRA
      Medical Specialities
      Health Care
    • Natera Appoints Minetta Liu, M.D. as Chief Medical Officer of Oncology

      AUSTIN, Texas, May 24, 2022  /PRNewswire/ -- Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing, today announced the appointment of Minetta Liu, M.D., as its new chief medical officer (CMO) of oncology. In this role, Dr. Liu will set the direction for the company's clinical and scientific roadmap in oncology, primarily to prove the clinical utility of Signatera™ and incorporate it into standard medical practice across tumor types. "I am very pleased to welcome Dr. Liu to Natera," said Solomon Moshkevich, general manager of oncology at Natera. "As a highly reg

      5/24/22 8:03:00 AM ET
      $NTRA
      Medical Specialities
      Health Care

    $NTRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CO-FOUNDER Sheena Jonathan sold $966,633 worth of shares (6,070 units at $159.25), decreasing direct ownership by 1% to 251,844 units (SEC Form 4)

      4 - Natera, Inc. (0001604821) (Issuer)

      5/13/25 9:35:05 PM ET
      $NTRA
      Medical Specialities
      Health Care
    • Director Marcus Gail Boxer exercised 4,000 shares at a strike of $24.42 and sold $606,433 worth of shares (4,000 units at $151.61) (SEC Form 4)

      4 - Natera, Inc. (0001604821) (Issuer)

      5/2/25 9:35:05 PM ET
      $NTRA
      Medical Specialities
      Health Care
    • CEO AND PRESIDENT Chapman Steven Leonard sold $1,047,702 worth of shares (6,980 units at $150.10), decreasing direct ownership by 4% to 185,182 units (SEC Form 4)

      4 - Natera, Inc. (0001604821) (Issuer)

      5/2/25 9:35:09 PM ET
      $NTRA
      Medical Specialities
      Health Care

    $NTRA
    Financials

    Live finance-specific insights

    See more
    • Natera Reports First Quarter 2025 Financial Results

      Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the first quarter ended March 31, 2025. Recent Strategic and Financial Highlights Generated total revenues of $501.8 million in the first quarter of 2025, compared to $367.7 million in the first quarter of 2024, an increase of 36.5%. Product revenues grew 37.1% over the same period. Generated a gross margin of 63.1% in the first quarter of 2025, compared to a gross margin of 56.7% in the first quarter of 2024. Processed approximately 855,100 tests in the first quarter of 2025, compared to approximately 735,800 tests in the first quarter of 2024, an increase of

      5/8/25 4:05:00 PM ET
      $NTRA
      Medical Specialities
      Health Care
    • Natera to Report its First Quarter Results on May 8, 2025

      Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its first quarter ended March 31, 2025, after the market closes on May 8, 2025. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information Event: Natera's First Quarter 2025 Financial Results Date: May 8, 2025 Time: 1:30 p.m. PT (4:30 p.m. ET) Live Dial-In: 1-888-596-4144 (Domestic) 1-646-968-2525 (International) Conference ID: 7684785 Webcast: https://events.q4inc.com/attendee/454317205 A webcast replay will be available at

      5/1/25 7:00:00 AM ET
      $NTRA
      Medical Specialities
      Health Care
    • Natera Reports Fourth Quarter and Full Year 2024 Financial Results

      Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the fourth quarter and full year ended December 31, 2024. Recent Financial Highlights Generated total revenues of $476.1 million in the fourth quarter of 2024, compared to $311.1 million in the fourth quarter of 2023, an increase of 53.0%. Product revenues grew 53.9% over the same period. Generated a gross margin of 62.9% in the fourth quarter of 2024, compared to a gross margin of 51.4% in the fourth quarter of 2023. Generated total revenues of $1,696.9 million in the full year of 2024, compared to $1,082.6 million in the full year 2023, an increase of 56.7%

      2/27/25 4:05:00 PM ET
      $NTRA
      Medical Specialities
      Health Care

    $NTRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • RBC Capital Mkts initiated coverage on Natera with a new price target

      RBC Capital Mkts initiated coverage of Natera with a rating of Outperform and set a new price target of $251.00

      3/13/25 8:17:14 AM ET
      $NTRA
      Medical Specialities
      Health Care
    • Barclays initiated coverage on Natera with a new price target

      Barclays initiated coverage of Natera with a rating of Overweight and set a new price target of $200.00

      1/23/25 7:51:22 AM ET
      $NTRA
      Medical Specialities
      Health Care
    • Jefferies resumed coverage on Natera with a new price target

      Jefferies resumed coverage of Natera with a rating of Buy and set a new price target of $142.00

      6/3/24 8:16:05 AM ET
      $NTRA
      Medical Specialities
      Health Care

    $NTRA
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Natera Inc.

      SCHEDULE 13G/A - Natera, Inc. (0001604821) (Subject)

      5/14/25 10:45:26 AM ET
      $NTRA
      Medical Specialities
      Health Care
    • SEC Form 10-Q filed by Natera Inc.

      10-Q - Natera, Inc. (0001604821) (Filer)

      5/8/25 7:35:38 PM ET
      $NTRA
      Medical Specialities
      Health Care
    • Natera Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Natera, Inc. (0001604821) (Filer)

      5/8/25 4:15:22 PM ET
      $NTRA
      Medical Specialities
      Health Care